Ligand Pharmaceuticals (NASDAQ:LGND) just reported results for the second quarter of 2024.
- Ligand Pharmaceuticals reported earnings per share of $1.40. This was above the analyst estimate for EPS of 98 cents.
- The company reported revenue of $41.53 million.
- This was 30.19% better than the analyst estimate for revenue of $31.90 million.